+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pharmacovigilance Market by Type (Cohort Event Monitoring, EHR Mining, Intensified ADR Reporting), Product Life Cycle (Phase I, Phase II, Phase III), Delivery Mode, Process Flow, Therapeutic Area, End-user - Global Forecast 2025-2030- Product Image
Pharmacovigilance Market by Type (Cohort Event Monitoring, EHR Mining, Intensified ADR Reporting), Product Life Cycle (Phase I, Phase II, Phase III), Delivery Mode, Process Flow, Therapeutic Area, End-user - Global Forecast 2025-2030- Product Image
Sale

Pharmacovigilance Market by Type (Cohort Event Monitoring, EHR Mining, Intensified ADR Reporting), Product Life Cycle (Phase I, Phase II, Phase III), Delivery Mode, Process Flow, Therapeutic Area, End-user - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 198 Pages
  • March 2025
  • Region: Global
  • 360iResearch™
  • ID: 5306611
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Pharmacovigilance Market grew from USD 10.24 billion in 2024 to USD 11.84 billion in 2025. It is expected to continue growing at a CAGR of 15.85%, reaching USD 24.76 billion by 2030.

Pharmacovigilance stands as a critical pillar in the pharmaceutical industry, ensuring that safety and efficacy remain at the forefront of drug development and post-market surveillance. In today’s dynamic healthcare environment, the systematic monitoring of adverse drug reactions not only safeguards patient health but also helps companies mitigate risks and sustain regulatory compliance. The growth in global healthcare demands, coupled with the rapid evolution of medical technologies, has driven stakeholders to adopt more proactive and sophisticated approaches to drug safety management. This transformation has paved the way for enhanced data analytics, real-time monitoring systems, and a more integrative approach to risk assessment. As the industry moves forward, the convergence of innovative methodologies with traditional safety practices has become essential to address the burgeoning challenges of an increasingly complex regulatory framework. This report provides a comprehensive analysis of the current state of pharmacovigilance, highlighting key trends, innovations, and strategic segments that collectively shape market dynamics.

Transformative Shifts Reshaping Pharmacovigilance Protocols

In recent years, the pharmacovigilance landscape has witnessed transformative shifts that challenge conventional practices and stimulate innovative approaches. The increasing integration of digital technologies has redefined how safety data is captured, processed, and evaluated. Advanced analytics, artificial intelligence, and machine learning algorithms now enable the swift identification of safety signals that may have previously gone undetected. Regulatory bodies are also pushing for more transparent and collaborative data-sharing environments, which are fostering a more harmonized global approach to patient safety.

Traditional methods have gradually given way to technology-driven frameworks, where real-time monitoring, electronic health record (EHR) mining, and automated adverse event reporting empower stakeholders with timely insights. The shift towards proactive surveillance is particularly evident in the adoption of targeted spontaneous reporting and intensified adverse drug reaction reporting practices. As these practices evolve, they not only enhance the efficacy of risk management systems but also improve decision-making processes and optimize resource allocation. This evolution underscores the necessity for a robust and agile pharmacovigilance system that can swiftly adapt to changes in regulatory landscapes while simultaneously embracing new data-driven technologies. Overall, the transformation in pharmacovigilance practices positions the industry to better manage safety risks and protect public health in a rapidly changing global ecosystem.

Key Segmentation Insights Driving Market Customization

The pharmacovigilance market is meticulously segmented to address diverse industry needs and optimize safety operations. When considering segmentation based on type, the market is studied across methodologies such as cohort event monitoring, EHR mining, intensified adverse drug reaction reporting, spontaneous reporting, and targeted spontaneous reporting, each contributing to a nuanced understanding of safety data. In parallel, the product life cycle segmentation encompasses critical phases including Phase I, Phase II, Phase III, Phase IV, and pre-clinical stages, ensuring that risk management strategies are tailored to the specific demands at every development milestone.

Segmentation based on delivery mode differentiates between in-house capabilities and outsourced solutions, reflecting varying operational preferences and resource allocation strategies. Further, process flow segmentation delves into key activities such as case data management, risk management systems, and signal detection. Notably, case data management itself is subdivided into case data analysis, case logging, and medical reviewing & reporting, while risk management systems are broken down into risk evaluation and risk mitigation subsystems. Signal detection is further detailed through adverse event analysis, adverse event logging, and adverse event review & reporting, emphasising a thorough approach to safety surveillance.

In addition, therapeutic area segmentation examines specialized domains including cardiovascular, infectious diseases, neurology, oncology, and respiratory conditions. Finally, segmentation based on end-user plays a vital role in differentiating requirements among biotechnology companies, medical device manufacturers, and pharmaceutical organizations. Together, these segmentation strategies offer a comprehensive framework that enables market players to fine-tune their operational strategies and align their safety protocols with both regulatory requirements and market expectations.

Based on Type, market is studied across Cohort Event Monitoring, EHR Mining, Intensified ADR Reporting, Spontaneous Reporting, and Targeted Spontaneous Reporting.

Based on Product Life Cycle, market is studied across Phase I, Phase II, Phase III, Phase IV, and Pre-clinical.

Based on Delivery Mode, market is studied across In-house and Outsourced.

Based on Process Flow, market is studied across Case Data Management, Risk Management System, and Signal Detection. The Case Data Management is further studied across Case Data Analysis, Case Logging, and Medical Reviewing & Reporting. The Risk Management System is further studied across Risk Evaluation System and Risk Mitigation System. The Signal Detection is further studied across Adverse Event Analysis, Adverse Event Logging, and Adverse Event Review & Reporting.

Based on Therapeutic Area, market is studied across Cardiovascular, Infectious Diseases, Neurology, Oncology, and Respiratory.

Based on End-user, market is studied across Biotechnology Companies, Medical Device Manufacturers, and Pharmaceuticals.

Key Regional Insights Illuminating Global Trends

Regional dynamics play a pivotal role in shaping the pharmacovigilance market, as varied healthcare infrastructures and regulatory environments propel distinct trends across different geographies. In the Americas, a strong emphasis on digital transformation and stringent regulatory standards is driving the adoption of innovative pharmacovigilance practices, thereby setting a benchmark for safety-related initiatives. The Americas region continues to see rapid integration of advanced analytics within its healthcare systems, reinforcing the commitment to enhanced patient safety.

In the combined region of Europe, the Middle East, and Africa, there is a noticeable drive towards harmonizing safety protocols and embracing collaborative data-sharing initiatives that bridge the gap between disparate regulatory frameworks. The push for more transparent and uniform practices across these regions is further accelerating the shift towards real-time surveillance and improved risk mitigation measures. Meanwhile, the Asia-Pacific region distinguishes itself as a hub for technological advancement and robust market growth, capitalizing on both emerging markets and established regulatory reforms. The diverse trends observed across these regions illustrate that while local conditions may differ, the global impetus is clear - harness the power of technology and data to lead the way in pharmacovigilance excellence.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights Highlighting Major Market Players

An array of leading companies is at the forefront of advancing pharmacovigilance methodologies and driving industry-wide innovation. Influential players such as Accenture, PLC and Bristol-Myers Squibb Company have been instrumental in developing state-of-the-art safety monitoring systems that strengthen compliance and risk management practices. Capgemini SE and ClinChoice continue to set high standards by integrating technology with comprehensive pharmacovigilance processes, thereby enhancing the accuracy and efficiency of safety data capture and analysis.

Other market leaders like F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, and HCL Technologies Limited have made significant investments in digital health solutions, transforming traditional risk management frameworks into dynamic, technology-enabled platforms. ICON PLC and Infosys Limited are also prime examples of companies leveraging innovative IT solutions to streamline case processing, while International Business Machines Corporation and IQVIA Inc. harness advanced analytics to detect subtle adverse event trends. The spectrum is further broadened by key contributions from ITclinical, Laboratory Corporation of America Holdings, Linical Co., Ltd., and Novartis AG, each playing a pivotal role in defining safety paradigms. Oracle Corporation, Parexel International, and Pfizer Inc. have similarly championed technological integration in safety surveillance. Complementing these are Quanticate International Limited, Sanofi S.A., Syneos Health, TAKE Solutions Limited, TATA Consultancy Services Limited, and Wipro Limited, all of which continue to contribute to building resilient, forward-thinking pharmacovigilance ecosystems that secure patient safety and optimize operational efficiency.

The report delves into recent significant developments in the Pharmacovigilance Market, highlighting leading vendors and their innovative profiles. These include Accenture, PLC, Bristol-Myers Squibb Company, Capgemini SE, ClinChoice, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, HCL Technologies Limited, ICON PLC, Infosys Limited, International Business Machines Corporation, IQVIA Inc., ITclinical, Laboratory Corporation of America Holdings, Linical Co., Ltd., Novartis AG, Oracle Corporation, Parexel International, Pfizer Inc., Quanticate International limited, Sanofi S.A., Syneos Health, TAKE Solutions Limited, TATA Consultancy Services Limited, and Wipro Limited.

Actionable Recommendations for Strategic Industry Advancement

To remain competitive in a rapidly evolving pharmacovigilance market, industry leaders must adopt a multi-faceted strategy that leverages both technological and operational innovation. Firstly, it is imperative to invest in advanced digital tools that streamline data collection and analysis to facilitate real-time monitoring. Embracing automation in adverse event reporting and signal detection can significantly reduce response times, thereby bolstering overall risk management strategies.

Secondly, organizations should prioritize building integrated frameworks that link disparate data sources across the drug development lifecycle. By aligning case data management with robust risk evaluation and mitigation systems, companies can ensure that every stage from pre-clinical research to post-market surveillance benefits from a cohesive safety net. This integrated approach not only heightens regulatory compliance but also enhances the ability to predict and respond to potential safety challenges before they escalate into major issues.

A third recommendation is to foster collaborative partnerships with technology providers and industry consortia. Such alliances can accelerate the adoption of best practices and promote the sharing of groundbreaking innovations. Leaders are encouraged to take proactive steps towards streamlining processes, which may include the reevaluation of current in-house versus outsourced delivery modes to optimize efficiency and cost-effectiveness.

Lastly, continuous professional development and cross-functional training are essential. Empowering teams with up-to-date knowledge on the latest regulatory guidelines and technological advancements will help sustain a culture of vigilance and innovation. By integrating these actionable recommendations into their operational strategies, industry leaders can position themselves at the forefront of pharmacovigilance excellence while effectively mitigating the inherent risks associated with drug safety.

Reinforcing the Path to Enhanced Drug Safety

The insights presented in this report underscore the dynamic and transformative nature of the pharmacovigilance market. As healthcare landscapes continue to shift, the integration of digital technologies, comprehensive segmentation strategies, and collaborative stakeholder initiatives remains paramount. The market is driven by an unyielding commitment to patient safety, with trends that signal a new era of real-time monitoring and advanced analytics. In sum, the evolving frameworks and robust methodologies not only facilitate compliance with global regulatory standards but also empower organizations to anticipate and mitigate risks more effectively. The journey towards enhanced drug safety is marked by both challenges and unprecedented opportunities, paving the way for transformative strategies that resonate across the entire pharmaceutical ecosystem.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing regulatory requirements for comprehensive drug safety monitoring and post-market surveillance
5.1.1.2. Advancements in AI, machine learning, and big data analytics driving improved adverse event detection
5.1.1.3. Rising global incidence of ADRs and growing public awareness fueling demand for pharmacovigilance services
5.1.2. Restraints
5.1.2.1. High operational costs and resource-intensive nature of implementing robust pharmacovigilance systems
5.1.3. Opportunities
5.1.3.1. Emerging markets in Asia-Pacific and Latin America offering growth opportunities due to healthcare investments
5.1.3.2. Potential for cloud-based real-time safety monitoring solutions enhancing pharmacovigilance processes
5.1.4. Challenges
5.1.4.1. Difficulty in integrating diverse data sources and ensuring interoperability across global systems
5.2. Market Segmentation Analysis
5.2.1. Type: Growing adoption of EHR mining to identify potential ADRs by analyzing patient data
5.2.2. End-user: Rising application of pharmacovigilance in medical device manufacturers to efficiently capture safety data and adverse event reports
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Pharmacovigilance Market, by Type
6.1. Introduction
6.2. Cohort Event Monitoring
6.3. EHR Mining
6.4. Intensified ADR Reporting
6.5. Spontaneous Reporting
6.6. Targeted Spontaneous Reporting
7. Pharmacovigilance Market, by Product Life Cycle
7.1. Introduction
7.2. Phase I
7.3. Phase II
7.4. Phase III
7.5. Phase IV
7.6. Pre-clinical
8. Pharmacovigilance Market, by Delivery Mode
8.1. Introduction
8.2. In-house
8.3. Outsourced
9. Pharmacovigilance Market, by Process Flow
9.1. Introduction
9.2. Case Data Management
9.2.1. Case Data Analysis
9.2.2. Case Logging
9.2.3. Medical Reviewing & Reporting
9.3. Risk Management System
9.3.1. Risk Evaluation System
9.3.2. Risk Mitigation System
9.4. Signal Detection
9.4.1. Adverse Event Analysis
9.4.2. Adverse Event Logging
9.4.3. Adverse Event Review & Reporting
10. Pharmacovigilance Market, by Therapeutic Area
10.1. Introduction
10.2. Cardiovascular
10.3. Infectious Diseases
10.4. Neurology
10.5. Oncology
10.6. Respiratory
11. Pharmacovigilance Market, by End-user
11.1. Introduction
11.2. Biotechnology Companies
11.3. Medical Device Manufacturers
11.4. Pharmaceuticals
12. Americas Pharmacovigilance Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Pharmacovigilance Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Pharmacovigilance Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Scenario Analysis
15.3.1. ProductLife Group's acquisition of Callisto enhances regulatory services and pharmacovigilance in the UK and EU
15.3.2. EVERSANA and Oracle collaborate to transform proactive pharmacovigilance with AI-driven innovations
15.3.3. Kenya and Malawi develop a partnership to advance pharmacovigilance and increase drug safety in Africa
15.3.4. Qinecsa Solutions expands administration in pharmacovigilance with strategic acquisition of Insife ApS
15.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. PHARMACOVIGILANCE MARKET MULTI-CURRENCY
FIGURE 2. PHARMACOVIGILANCE MARKET MULTI-LANGUAGE
FIGURE 3. PHARMACOVIGILANCE MARKET RESEARCH PROCESS
FIGURE 4. PHARMACOVIGILANCE MARKET SIZE, 2024 VS 2030
FIGURE 5. GLOBAL PHARMACOVIGILANCE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 9. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2024 VS 2030 (%)
FIGURE 11. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2024 VS 2030 (%)
FIGURE 13. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2024 VS 2030 (%)
FIGURE 15. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 17. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 18. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 19. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 20. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 21. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 22. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 23. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 24. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 25. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 28. PHARMACOVIGILANCE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 29. PHARMACOVIGILANCE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. PHARMACOVIGILANCE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PHARMACOVIGILANCE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. PHARMACOVIGILANCE MARKET DYNAMICS
TABLE 7. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COHORT EVENT MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY EHR MINING, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY INTENSIFIED ADR REPORTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SPONTANEOUS REPORTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TARGETED SPONTANEOUS REPORTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE IV, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRE-CLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY OUTSOURCED, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE LOGGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY MEDICAL REVIEWING & REPORTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK EVALUATION SYSTEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK MITIGATION SYSTEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT LOGGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT REVIEW & REPORTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY MEDICAL DEVICE MANUFACTURERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 58. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 59. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. CANADA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 76. CANADA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 77. CANADA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 78. CANADA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 79. CANADA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 80. CANADA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 81. CANADA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 82. CANADA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 83. CANADA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 85. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 86. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 87. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 88. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 89. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 90. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 91. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 92. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 103. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 104. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 105. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 106. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 107. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 108. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 109. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 110. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 111. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 112. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 113. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 114. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 115. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 116. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 117. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 118. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 119. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 120. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 121. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 122. CHINA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 123. CHINA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 124. CHINA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 125. CHINA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 126. CHINA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 127. CHINA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 128. CHINA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 129. CHINA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 130. CHINA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 131. INDIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 132. INDIA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 133. INDIA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 134. INDIA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 135. INDIA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 136. INDIA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 137. INDIA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 138. INDIA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 139. INDIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 140. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 141. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 142. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 143. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 144. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 145. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 146. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 147. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 148. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 149. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 150. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 151. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 152. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 153. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 154. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 155. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 156. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 157. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 158. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 159. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 160. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 161. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 162. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 163. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 164. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 165. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 166. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 167. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 168. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 169. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 170. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 171. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 172. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 173. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 174. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 175. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 176. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 177. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 178. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 179. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 180. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 181. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 182. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 183. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 184. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 185. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 186. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 187. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 188. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 189. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 190. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 191. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 192. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 193. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 194. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 195. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 196. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 197. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 198. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 199. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 200. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 201. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 202. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 203. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 204. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 205. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 206. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 207. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 208. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 209. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 210. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 211. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 212. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 213. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 214. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 215. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 216. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 217. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 218. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 219. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 220. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 231. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 232. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 233. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 234. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 235. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 236. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 237. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 238. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 239. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 240. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 241. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 242. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 243. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 244. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 245. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 246. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 247. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 248. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 249. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 250. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 251. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 252. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 253. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 254. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 255. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 256. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 257. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 258. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 259. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 260. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 261. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 262. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 263. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 264. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 265. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 266. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 267. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 268. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 269. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 270. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 271. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 272. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 273. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 274. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 275. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 276. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 277. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 278. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 279. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 280. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 281. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 282. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 283. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 284. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 285. ITALY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 286. ITALY PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 287. ITALY PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 288. ITALY PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 289. ITALY PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 290. ITALY PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 291. ITALY PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 292. ITALY PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 293. ITALY PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 294. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 295. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 296. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 297. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 298. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 299. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 300. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 301. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 302. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 303. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 304. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 305. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 306. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 307. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 308. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 309. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 310. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 311. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 312. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 313. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 314. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 315. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 316. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 317. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 318. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 319. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 320. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 321. POLAND PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 322. POLAND PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 323. POLAND PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 324. POLAND PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 325. POLAND PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 326. POLAND PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 327. POLAND PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 328. POLAND PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 329. POLAND PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 330. QATAR PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 331. QATAR PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 332. QATAR PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 333. QATAR PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 334. QATAR PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 335. QATAR PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 336. QATAR PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 337. QATAR PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 338. QATAR PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 339. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 340. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 341. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 342. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 343. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 344. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 345. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 346. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 347. RUSSIA PHARMACOVIGI

Companies Mentioned

  • Accenture, PLC
  • Bristol-Myers Squibb Company
  • Capgemini SE
  • ClinChoice
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • HCL Technologies Limited
  • ICON PLC
  • Infosys Limited
  • International Business Machines Corporation
  • IQVIA Inc.
  • ITclinical
  • Laboratory Corporation of America Holdings
  • Linical Co., Ltd.
  • Novartis AG
  • Oracle Corporation
  • Parexel International
  • Pfizer Inc.
  • Quanticate International limited
  • Sanofi S.A.
  • Syneos Health
  • TAKE Solutions Limited
  • TATA Consultancy Services Limited
  • Wipro Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages198
PublishedMarch 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 11.84 Billion
Forecasted Market Value ( USD ) by 2030 $ 24.76 Billion
Compound Annual Growth Rate15.8%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Pharmacovigilance Market Size, Share & Trends Analysis Report by Product Life Cycle, Service Provider (In-house, Contract Outsourcing), Type, Therapeutic Area, Process Flow, End Use, Region, and Segment Forecasts, 2024-2030 - Product Image

Pharmacovigilance Market Size, Share & Trends Analysis Report by Product Life Cycle, Service Provider (In-house, Contract Outsourcing), Type, Therapeutic Area, Process Flow, End Use, Region, and Segment Forecasts, 2024-2030

  • Report
  • 295 Pages
  • Global
From
Pharmacovigilance & Drug Safety Software Market by Product, Clinical Trial, Distribution, End User - Global Forecast 2025-2030 - Product Image

Pharmacovigilance & Drug Safety Software Market by Product, Clinical Trial, Distribution, End User - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Pharmacovigilance Market Report by Service Provider, Product Life Cycle, Type, Process Flow, Therapeutic Area, End Use, and Region 2024-2032 - Product Image

Pharmacovigilance Market Report by Service Provider, Product Life Cycle, Type, Process Flow, Therapeutic Area, End Use, and Region 2024-2032

  • Report
  • 135 Pages
  • Global
From
Pharmacovigilance and Drug Safety Software Market Report by Functionality, Delivery Mode, End User, and Region 2024-2032 - Product Image

Pharmacovigilance and Drug Safety Software Market Report by Functionality, Delivery Mode, End User, and Region 2024-2032

  • Report
  • 137 Pages
  • Global
From
Pharmacovigilance - Global Strategic Business Report - Product Image

Pharmacovigilance - Global Strategic Business Report

  • Report
  • 88 Pages
  • Global
From

About the Pharmacovigilance Market

The Pharmacovigilance market is a subset of the Healthcare Services industry, focusing on the monitoring and assessment of the safety of pharmaceutical products. It involves the collection, analysis, and reporting of adverse events related to the use of drugs, as well as the identification of potential risks associated with their use. Pharmacovigilance activities are conducted by pharmaceutical companies, regulatory authorities, and healthcare professionals. Pharmacovigilance activities are essential for the safe and effective use of drugs, as they help to identify potential risks and ensure that the benefits of the drug outweigh the risks. Pharmacovigilance also helps to ensure that the drug is used appropriately and that any adverse events are reported and addressed. Some companies in the Pharmacovigilance market include Parexel, Quintiles, Covance, PRA Health Sciences, and ICON. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.